A research report published just yesterday by Allied Market research affirms that the global viral vectors and plasmid DNA manufacturing market generated $918.37 million in 2019, and is projected to reach $4.97 billion by 2027, growing at a CAGR of 24.9% from 2020 to 2027. 1
BioCentriq™ is offering a 4-Day Virtual Training October 19-22 on the design and manufacturing of viral vectors for gene therapy.
As of today, there are still several spots available in Intro to the Design & Manufacturing of Viral Vectors for Gene Therapy.
“Our course is designed to create the workforce of the future “stated Haro Hartounian, Ph.D., senior vice-president and general manager, NJII. “We must help scientists from around the globe gain a detailed understanding of upstream and downstream processing of viral vectors so they can support the incredible demand we are seeing in the market. “
The course, led by NJII and NJIT staff and faculty, includes 16 hours of interactive, live, on-line instruction held over four days. It will focus on viral vector theory, technical demonstrations of bioreactors, demonstration of chromatography, principles of tangential flow filtration (TFF) and scale-up topics.
Attendance is limited to 20 scientists and engineers from the industry. Class size is kept small to ensure maximum engagement and interaction. Attendees must have a basic understanding of cell culture, conventional culture methods and chromatography (affinity, protein capture).
Full details on the course can be found here.